Research programme: anticancer monoclonal antibodies - Innate Pharma

Drug Profile

Research programme: anticancer monoclonal antibodies - Innate Pharma

Alternative Names: IPH-4201

Latest Information Update: 18 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Genoa
  • Developer Innate Pharma
  • Class Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pancreatic cancer

Most Recent Events

  • 18 Feb 2010 Discontinued - Preclinical for Pancreatic cancer in France (Parenteral)
  • 01 Dec 2008 Preclinical trials in Pancreatic cancer in France (Parenteral)
  • 15 Mar 2002 Preclinical trials in Cancer in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top